FDA Inspection 1123748 — Fresenius Kabi USA LLC

Fresenius Kabi USA LLC — FEI 1450022

The FDA completed an inspection of Fresenius Kabi USA LLC on May 18, 2020 in Melrose Park, IL. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 6 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
May 18, 2020
Fiscal Year
2020
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Melrose Park, IL (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
121521 CFR 211.67(b)Written procedures not established/followed
144821 CFR 211.111Establishment of time limitations
145121 CFR 211.113(b)Procedures for sterile drug products
201221 CFR 211.188(b)Batch production and Batch Control Record Requirements
202721 CFR 211.192Investigations of discrepancies, failures